Literature DB >> 29147615

Tumor-associated neutrophils induce apoptosis of non-activated CD8 T-cells in a TNFα and NO-dependent mechanism, promoting a tumor-supportive environment.

Janna Michaeli1, Merav E Shaul1, Inbal Mishalian1, Avi-Hai Hovav2, Liran Levy1, Lidia Zolotriov1, Zvi Granot3, Zvi G Fridlender1.   

Abstract

The role of neutrophils in tumor progression has become in recent years a subject of growing interest. Tumor-associated neutrophils (TANs), which constitute an important portion of the tumor microenvironment, promote immunosuppression in advanced tumors by modulating the proliferation, activation and recruitment of a variety of immune cell types. Studies which investigated the consequences of manipulating TAN polarization suggest that the impact of these neutrophils on tumor progression is considerably mediated by and dependent on the presence of CD8 T-cells. It has been previously shown that granulocytic myeloid regulatory cells, i.e. TANs and granulocytic myeloid-derived suppressor cells (G-MDSCs) are capable of suppressing CD8 T-cell proliferation and affect their activation. In the current study, we find that in addition, TANs isolated from different models of murine cancer promote immunosuppression by strongly inducing CD8 T-cell apoptosis. We demonstrate that the TNFα pathway in TANs is critical for the induction of apoptosis, and that the mechanism through which apoptosis is induced involves the production of NO, but not ROS. In the absence of pre-activation, TANs are capable of activating CD8 T-cells, but specifically induce the apoptosis of non-activated CD8+CD69- cells. Despite this contradictive effect on T-cell function, we show in vivo that TANs suppress the anti-tumor effect of CD8 T-cells and abolish their ability to delay tumor growth. Our results add another important layer on the understanding of the possible mechanisms by which TANs regulate the anti-tumor immune response mediated by CD8 T-cells, therefore promoting a tumor-supportive environment.

Entities:  

Keywords:  Activation; CD8 cytotoxic T-cell; apoptosis; immunotolerance; lung cancer; tumor-associated neutrophils

Year:  2017        PMID: 29147615      PMCID: PMC5674962          DOI: 10.1080/2162402X.2017.1356965

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN: 2162-4011            Impact factor:   8.110


  58 in total

1.  Tumor-infiltrating macrophages induce apoptosis in activated CD8(+) T cells by a mechanism requiring cell contact and mediated by both the cell-associated form of TNF and nitric oxide.

Authors:  M Saio; S Radoja; M Marino; A B Frey
Journal:  J Immunol       Date:  2001-11-15       Impact factor: 5.422

2.  Tumor-associated neutrophils (TAN) develop pro-tumorigenic properties during tumor progression.

Authors:  Inbal Mishalian; Rachel Bayuh; Liran Levy; Lida Zolotarov; Janna Michaeli; Zvi Gregorio Fridlender
Journal:  Cancer Immunol Immunother       Date:  2013-10-04       Impact factor: 6.968

3.  Type I IFNs induce anti-tumor polarization of tumor associated neutrophils in mice and human.

Authors:  Lisa Andzinski; Nadine Kasnitz; Stephanie Stahnke; Ching-Fang Wu; Marcus Gereke; Maren von Köckritz-Blickwede; Bastian Schilling; Sven Brandau; Siegfried Weiss; Jadwiga Jablonska
Journal:  Int J Cancer       Date:  2015-12-17       Impact factor: 7.396

4.  Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase.

Authors:  Catherine Uyttenhove; Luc Pilotte; Ivan Théate; Vincent Stroobant; Didier Colau; Nicolas Parmentier; Thierry Boon; Benoît J Van den Eynde
Journal:  Nat Med       Date:  2003-09-21       Impact factor: 53.440

5.  Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy.

Authors:  C Marcela Diaz-Montero; Mohamed Labib Salem; Michael I Nishimura; Elizabeth Garrett-Mayer; David J Cole; Alberto J Montero
Journal:  Cancer Immunol Immunother       Date:  2008-04-30       Impact factor: 6.968

6.  The localization and density of immune cells in primary tumors of human metastatic colorectal cancer shows an association with response to chemotherapy.

Authors:  Niels Halama; Sara Michel; Matthias Kloor; Inka Zoernig; Thora Pommerencke; Magnus von Knebel Doeberitz; Peter Schirmacher; Jürgen Weitz; Niels Grabe; Dirk Jäger
Journal:  Cancer Immun       Date:  2009-02-19

7.  Survival of residual neutrophils and accelerated myelopoiesis limit the efficacy of antibody-mediated depletion of Ly-6G+ cells in tumor-bearing mice.

Authors:  Katrin Moses; Johanna C Klein; Linda Männ; Anika Klingberg; Matthias Gunzer; Sven Brandau
Journal:  J Leukoc Biol       Date:  2016-01-27       Impact factor: 4.962

8.  Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation.

Authors:  S T Ju; D J Panka; H Cui; R Ettinger; M el-Khatib; D H Sherr; B Z Stanger; A Marshak-Rothstein
Journal:  Nature       Date:  1995-02-02       Impact factor: 49.962

9.  Neutrophils recruit regulatory T-cells into tumors via secretion of CCL17--a new mechanism of impaired antitumor immunity.

Authors:  Inbal Mishalian; Rachel Bayuh; Evgeniy Eruslanov; Janna Michaeli; Liran Levy; Lida Zolotarov; Sunil Singhal; Steven M Albelda; Zvi Granot; Zvi G Fridlender
Journal:  Int J Cancer       Date:  2014-02-27       Impact factor: 7.396

Review 10.  Distinct Functions of Neutrophil in Cancer and Its Regulation.

Authors:  Zvi Granot; Jadwiga Jablonska
Journal:  Mediators Inflamm       Date:  2015-11-16       Impact factor: 4.711

View more
  42 in total

Review 1.  Neutrophils as Orchestrators in Tumor Development and Metastasis Formation.

Authors:  Lydia Kalafati; Ioannis Mitroulis; Panayotis Verginis; Triantafyllos Chavakis; Ioannis Kourtzelis
Journal:  Front Oncol       Date:  2020-12-10       Impact factor: 6.244

Review 2.  Recent advances on the crosstalk between neutrophils and B or T lymphocytes.

Authors:  Sara Costa; Dalila Bevilacqua; Marco A Cassatella; Patrizia Scapini
Journal:  Immunology       Date:  2018-10-10       Impact factor: 7.397

Review 3.  Neutrophil plasticity in the tumor microenvironment.

Authors:  Morgan A Giese; Laurel E Hind; Anna Huttenlocher
Journal:  Blood       Date:  2019-03-21       Impact factor: 22.113

4.  An Overview of Advances in Cell-Based Cancer Immunotherapies Based on the Multiple Immune-Cancer Cell Interactions.

Authors:  Jialing Zhang; Stephan S Späth; Sherman M Weissman; Samuel G Katz
Journal:  Methods Mol Biol       Date:  2020

5.  Mature neutrophils suppress T cell immunity in ovarian cancer microenvironment.

Authors:  Kelly L Singel; Tiffany R Emmons; Anm Nazmul H Khan; Paul C Mayor; Shichen Shen; Jerry T Wong; Kayla Morrell; Kevin H Eng; Jaron Mark; Richard B Bankert; Junko Matsuzaki; Richard C Koya; Anna M Blom; Kenneth R McLeish; Jun Qu; Sanjay Ram; Kirsten B Moysich; Scott I Abrams; Kunle Odunsi; Emese Zsiros; Brahm H Segal
Journal:  JCI Insight       Date:  2019-03-07

6.  Ultrasound cavitation enhanced chemotherapy: In vivo research and clinical application.

Authors:  Zhiyong Shen; Jingjing Shao; Jianquan Zhang; Weixing Qu
Journal:  Exp Biol Med (Maywood)       Date:  2020-06-20

Review 7.  Tumor Associated Neutrophils. Their Role in Tumorigenesis, Metastasis, Prognosis and Therapy.

Authors:  Maria Teresa Masucci; Michele Minopoli; Maria Vincenza Carriero
Journal:  Front Oncol       Date:  2019-11-15       Impact factor: 6.244

Review 8.  Neutrophils in Tumorigenesis: Missing Targets for Successful Next Generation Cancer Therapies?

Authors:  Fabrice Tolle; Viktor Umansky; Jochen Utikal; Stephanie Kreis; Sabrina Bréchard
Journal:  Int J Mol Sci       Date:  2021-06-23       Impact factor: 5.923

Review 9.  Tumor Immune Microenvironment and Immunosuppressive Therapy in Hepatocellular Carcinoma: A Review.

Authors:  Kyoko Oura; Asahiro Morishita; Joji Tani; Tsutomu Masaki
Journal:  Int J Mol Sci       Date:  2021-05-28       Impact factor: 5.923

Review 10.  Immunotherapy in Pancreatic Adenocarcinoma: Beyond "Copy/Paste".

Authors:  Robert Hester; Pawel K Mazur; Florencia McAllister
Journal:  Clin Cancer Res       Date:  2021-06-30       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.